With the growing use of real-world evidence (RWE) to support regulatory approvals of new anti-cancer medicines in Europe and the USA, can this type of research ensure greater inclusion of women, the elderly, diverse ethnic groups, those with rare cancers and other under-represented populations in oncology studies?

According to Prof. Urania Dafni, high quality real-world evidence can provide broader information and more generalisable conclusions to verify the clinical applicability of evidence from RCTs 

Promising results with cancer vaccines based on specific antigen mutations in individual tumours, and typically used in combination with checkpoint inhibitors, are fuelling an upsurge of interest in cancer vaccination for patients with established cancer, explains Prof. Pedro Romero. 

However, researchers’ concerns about missing opportunities to publish their real-world evidence-based papers in high-ranked scientific journals are justified to some extent due to lack of ‘best practices’ from publishers and suitable peer reviewers for these study designs

This year’s recipient of the TAT Honorary Award Prof. Ruth Plummer, retraces the most significant milestones of her career in early phase studies